Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Equity Consolidated Statement of Equity

v3.20.1
Consolidated Statement of Equity Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Non-controlling Interests
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period, shares at Mar. 31, 2017   32,365,553              
Balance, beginning of period at Mar. 31, 2017 $ 312,502 $ 32 $ 219,284 $ 136,899 $ 4,622 $ (48,335)      
Issuance of common stock in exercise of stock options, shares 88,084 42,636              
Issuance of common stock in exercise of stock options $ 300   300            
Issuance of restricted stock as deferred compensation to employees and directors, shares             20,216    
Issuance of common stock in lieu of compensation, shares               43,445 20,489
Stock compensation expense 3,519   3,519            
Excess tax deduction from stock options (481)   (481)            
Net income (loss) 11,913     11,913          
Foreign curency translation adjustment 12,030         12,030      
Interest rate swap 34         34      
Other (270)         (270)      
Income attributable to non-controlling interests 1,306       1,306        
Balance, end of period, shares at Mar. 31, 2018   32,492,339              
Balance, end of period at Mar. 31, 2018 340,853 $ 32 222,622 148,812 5,928 (36,541)      
Issuance of common stock in exercise of stock options, shares   37,906              
Issuance of common stock in exercise of stock options $ 396   396            
Issuance of restricted stock as deferred compensation to employees and directors, shares 20,064           20,064    
Issuance of common stock in lieu of compensation, shares               51,775 22,116
Issuance of common stock as deferred compensation to employees $ 1 $ 1              
Stock compensation expense 4,148   4,148            
Excess tax deduction from stock options (598)   (598)            
Net income (loss) 22,756     22,756          
Foreign curency translation adjustment (13,233)         (13,233)      
Interest rate swap 825         825      
Other 825                
Noncontrolling Interest, Increase from Business Combination (5,665)       5,665        
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (947)                
Remeasurement of non-controlling interest 0   (3,528)   3,528        
Income attributable to non-controlling interests $ 413       413        
Balance, end of period, shares at Mar. 31, 2019 32,624,200 32,624,200              
Balance, end of period at Mar. 31, 2019 $ 348,949 $ 33 223,040 170,621 4,204 (48,949)      
Issuance of common stock in exercise of stock options, shares   159,062              
Issuance of common stock in exercise of stock options 1,016   1,016            
Issuance of restricted stock as deferred compensation to employees and directors, shares   26,608         26,608    
Issuance of common stock in lieu of compensation, shares               59,570 47,378
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 4,960   4,960            
Excess tax deduction from stock options (969)   (969)            
Net income (loss) 11,938     11,938          
Foreign curency translation adjustment (15,485)         (15,485)      
Other 540         540      
Remeasurement of non-controlling interest 0   (306)   306        
Purchase of non-controlling interest (4,508)       (4,508)        
Income attributable to non-controlling interests $ (2)       (2)        
Balance, end of period, shares at Mar. 31, 2020 32,916,818 32,916,818              
Balance, end of period at Mar. 31, 2020 $ 346,439 $ 33 $ 227,741 $ 182,559 $ 0 $ (63,894)